This meta-analysis reveals that the combination of erlotinib and bevacizumab can prolong progression-free survival but not overall survival compared to erlotinib alone in advanced EGFR-mutant non-small cell lung cancer. Here, EGFR is linked to non-small cell lung carcinoma.